PPD dampens takeover talk
July 19, 2011 in Global Markets News
BANGALORE |
BANGALORE (Reuters) – Pharmaceutical Product Development Inc (PPDI.O) said its board had asked management to review its strategic plan, but was not in talks with other clinical research providers, a day after a media report said the company was looking to sell itself.
The drug research services provider’s shares rose as much as 18 percent earlier Monday. They closed up 10 percent at $30.74 on Nasdaq.
PPD could fetch around $4 billion, or about $35-$37 a share, industry analysts said, reacting to a report on The Wall Street Journal on Sunday, adding that a private equity deal was more probable than a strategic transaction.
“As a premier late-stage focused contract research organization with a growing international presence, PPD is well-positioned to capitalize on Big Pharma’s emphasis on Phase II-IV global trials,” BBT analyst James Kumpel said.
PPD, which mostly provides late-stage drug research services to drugmakers, has a market capitalization of $3.15 billion, according to Thomson Reuters data.
While the entire sector was badly hit during the credit crunch with several research-stage biotechs going belly up or halting certain drug programs due to lack of money, the industry is finally seeing a resurgence in bookings.
However, PPD’s valuation has taken a hit over the past quarter and the shares lost 12 percent of their value since the company posted a weak quarterly profit in April, hurt by higher cancellations.
“PPD has been trading at a fairly noticeable discount to its peer group — 10-15 percent discount — despite having the best balance sheet,” Robert W. Baird analyst Eric Coldwell said.
“I don’t put high odds on a possible deal, but it definitely makes a lot of sense for PPD,” he added.
The article mentioned that PPD could see interest from private equity or other contract research firms.
BBT analyst Kumpel mentioned that apart from PE firms, there are not many natural buyers for the company and it was not clear “what a buyer would do to further improve margins or operating performance.”
There has been a slew of PE takeovers in the health sector recently, including Apax Partners’ APAX.UL $5 billion deal for Kinetic Concepts Inc (KCI.N), TPG Capital’s TPG.UL $2 billion buy of diagnostics firm Immucor (BLUD.O) and KKR’s (KKR.N) $2.38 billion buyout of Pfizer’s (PFE.N) Capsugel unit.
Last year, PPD’s rival Charles River Laboratories International Inc (CRL.N) had to shelve its plan of buying Chinese peer Wuxi PharmaTech (WX.N) for $1.6 billion after investors and proxy advisory firms opposed the deal.
Earlier this year, INC Research, a privately-held CRO, bought Kendle International Inc KNDL.O for $232 million.
Other large publicly-traded CROs includes Covance Inc (CVD.N) and Icon (ICON.I) (ICLR.O), with privately-held Quintiles being the other major player.
BBT makes a market in the securities of PPD and reported that it expects to receive compensation for investment banking services from the company in the next three months.
(Reporting by Esha Dey and Shravya Jain in Bangalore; Editing by Joyjeet Das, Prem Udayabhanu)